The Fort Worth Press - Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference

USD -
AED 3.672507
AFN 65.000291
ALL 82.302472
AMD 357.809202
ANG 1.790403
AOA 917.999875
ARS 1549.753496
AUD 1.483019
AWG 1.8
AZN 1.695071
BAM 1.7757
BBD 2.012982
BDT 124.44505
BGN 1.77347
BHD 0.37742
BIF 3001.498025
BMD 1
BND 1.288366
BOB 11.659547
BRL 5.786199
BSD 0.99941
BTN 93.823002
BWP 13.990966
BYN 3.003223
BYR 19600
BZD 2.010077
CAD 1.43023
CDF 2314.999897
CHF 0.83989
CLF 0.025392
CLP 999.349858
CNY 6.67175
CNH 6.664955
COP 3317.97
CRC 445.37243
CUC 1
CUP 23.986201
CVE 100.108947
CZK 22.199349
DJF 177.719794
DKK 6.79576
DOP 60.748576
DZD 137.03898
EGP 53.677976
ERN 15
ETB 164.058597
EUR 0.90911
FJD 2.280097
FKP 0.756558
GBP 0.758415
GEL 2.590107
GGP 0.756558
GHS 11.709483
GIP 0.756558
GMD 73.99989
GNF 8855.599437
GTQ 7.63916
GYD 209.138162
HKD 7.846125
HNL 26.880632
HRK 6.831965
HTG 130.99394
HUF 331.400499
IDR 18258.7
ILS 3.24365
IMP 0.756558
INR 93.89715
IQD 1515.309712
IRR 1913737.499047
ISK 124.359748
JEP 0.756558
JMD 158.482001
JOD 0.709033
JPY 159.536496
KES 129.969693
KGS 87.449398
KHR 4098.364377
KMF 447.000415
KPW 900.00035
KRW 1335.549942
KWD 0.31161
KYD 0.833012
KZT 444.73296
LAK 22505.595075
LBP 89510.130151
LKR 332.650884
LRD 169.925324
LSL 16.93731
LTL 2.95274
LVL 0.60489
LYD 6.457851
MAD 9.963139
MDL 18.281771
MGA 4546.321093
MKD 55.927629
MMK 2099.568705
MNT 3604.028735
MOP 8.07799
MRU 40.587408
MUR 47.809734
MVR 15.398196
MWK 1733.209252
MXN 18.56698
MYR 4.093498
MZN 63.90174
NAD 16.93731
NGN 1345.220271
NIO 36.779626
NOK 9.64499
NPR 150.11644
NZD 1.81728
OMR 0.384499
PAB 0.999532
PEN 3.408766
PGK 4.563138
PHP 63.886011
PKR 276.374515
PLN 4.001925
PYG 6202.732761
QAR 3.653729
RON 4.860198
RSD 106.911017
RUB 82.600372
RWF 1476.632544
SAR 3.763042
SBD 8.097697
SCR 13.916252
SDG 601.493572
SEK 10.097505
SGD 1.289165
SHP 0.752984
SLE 23.05065
SLL 20969.503664
SOS 571.259959
SRD 37.4535
STD 20697.981008
STN 22.241387
SVC 8.745744
SYP 13002.000337
SZL 16.932226
THB 33.906
TJS 9.210795
TMT 3.5
TND 3.021631
TOP 2.40776
TRY 50.38997
TTD 6.787708
TWD 32.944402
TZS 2650.074057
UAH 45.435091
UGX 4147.791748
UYU 40.582868
UZS 12004.176313
VES 912.87925
VND 25764
VUV 120.719595
WST 2.810584
XAF 596.337034
XAG 0.021318
XAU 0.000260262813
XCD 2.70255
XCG 1.801394
XDR 0.707052
XOF 596.337034
XPF 108.275455
YER 236.550076
ZAR 16.993275
ZMK 9001.205356
ZMW 20.4664
ZWL 321.999592
SSP 5945.381189
MXV 2.083467
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference

Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in late 2025/early 2026

Text size:

SAN FRANCISCO, CA / ACCESS Newswire / February 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Dr. Karen Brunke, Jaguar's EVP of Corporate and Business Development and Acting CEO of Magdalena Biosciences, Inc. (Magdalena), the joint venture formed by Jaguar and Filament Health Corp. (OTCQB:FLHLF) (CBOE CA:FH) (FSE:7QS) to develop novel, natural prescription medicines derived from plants for mental health indications, is presenting in person on Monday, February 10, 2025 at 2:30 PM Eastern at the BIO CEO & Investor Conference in New York City.

"I very much look forward to providing an overview of Magdalena at this conference and meeting with potential partners and investors at this event," Dr. Brunke said. "We expect Magdalena's lead botanical drug candidate, MB2500, to soon be IND-enabled for one of the following indications: cognitive deficit in schizophrenia or executive dysfunction in attention deficit hyperactivity disorder (ADHD). MB2500 may have the potential to serve as a first-ever treatment for the cognitive deficit that goes untreated in schizophrenia, which is a huge unmet medical need. Schizophrenia is a disease of cognitive deficit, a deficit which appears as much as a decade before onset of psychotic symptoms,1 but no approved drug currently exists to treat cognitive deficit in schizophrenia patients."

MB2500 is derived from a well characterized plant that has been in use by local populations for centuries, and has been shown to have both neuroprotective and cognitive enhancing properties, but has never been put through the rigorous clinical testing required for FDA approval. One or two more Magdalena botanical drug candidates for mental health indications are planned to be IND-enabled in late 2025/early 2026.

ADHD, a $25 billion global market,2 is a neurodevelopmental disorder characterized by the core symptoms of hyperactivity, inattentiveness, and impulsivity, and there is a growing need for safer ADHD treatments. Schizophrenia is a chronic, disabling mental illness that affects approximately one percent of the U.S. population.3 The global schizophrenia market is projected to grow to $13.41 billion by 2032, according to a market research report by Market Research Future.4

The mission of Magdalena, which is currently approximately 40-percent owned by Jaguar, is to develop novel, safe, efficacious next-generation psychoactive FDA-approved plant-based drugs under FDA Botanical Guidance for mental health indications including schizophrenia, anxiety, depression, and ADHD. Botanical drug candidates have a long history of use by traditional psychiatrists and may have the potential to serve as a new class of plant-based psychoactive drugs which are safe for daily dosing.

"Our approach is paradigm-shifting in drug development as we expect to go from plant extract to proof-of-concept (POC) human studies in 12-24 months - a huge time and cost savings which also, based on the history of human medicinal use of the plants, has a higher probability of success," said Dr. Brunke.

About Botanicals Drugs

Botanicals drugs are defined by the U.S. Food and Drug Administration (FDA) as "products from plant materials, algae, macroscopic fungi, and combinations thereof." Many botanical drugs have a long history of safe use in traditional medicines, which may be documented and reviewed in scientific literature. Existing scientific literature on safety may accelerate the safety review process for a botanical drug, reducing the scope and financial burden for extensive safety studies. The FDA has established guidance on botanical drug development and recognizes the complexity of botanical drugs. Additionally, botanical drugs, by virtue of their complexity, have the added benefit of being difficult to genericize. Hence there are often multiple opportunities for creating 'trade-secrets,' as well as novel patents around a botanical drug substance, its processing, its formulation, and so forth.

The Growing Market for Medicines Derived from Psychoactive Plants

According to the World Health Organization, one in four people in the world will be affected by mental or neurological disorders at some point in their lives. Around 450 million people currently suffer from such conditions, placing mental disorders among the leading causes of ill-health and disability worldwide. Among children, ADHD is the most common psychiatric disorder, disrupting learning and social behaviors. Common mental health conditions include depression, PTSD, anxiety, addiction, bipolar disorder (formerly called manic-depressive illness or manic depression), and anorexia nervosa, and expand to include neuro-degenerative diseases such as Parkinson's, Alzheimer's disease, and ALS (amyotrophic lateral sclerosis), among others. Substance use disorders occur when the recurring use of alcohol and/or drugs causes clinically significant impairment, including health problems, disability, and failure to meet major responsibilities at work, home, or school. The Lancet Commission, a group of experts in neuroscience, psychiatry, public health, and related fields, estimates that the cost of mental disorders, currently on the rise in every country, will reach $16 trillion by 2030, including costs associated with lost productivity.

About Filament Health (OTCQB:FLHLF) (CBOE CA:FH) (FSE:7QS)

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with what we believe to be the first-ever natural psychedelic drug candidates.

Learn more at www.filament.health and on Twitter, Instagram and LinkedIn.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Magdalena management will present at the 2025 BIO CEO & Investor Conference, the expectation that MB2500 will soon be IND-enabled and ready to enter the clinic for the first of two indications, the expectation that MB2500 may have the potential to serve as a first-ever treatment for the cognitive deficit that goes untreated in schizophrenia, the expectation that Magdalena may submit an IND application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as schizophrenia and ADHD, the expectation that 1-2 more additional Magdalena botanical drug candidates for mental health indications may be IND-enabled in late 2025/early 2026 and submitted as IND applications in late 2025/early 2026, the expectation that MB2500 may have the potential to be an effective treatment for ADHD or the cognitive deficit in schizophrenia, the expectation that botanical drug candidates may have the potential to serve as a new class of plant-based psychoactive drugs which are safe for daily at-home dosing, Magdalena's expectation that Magdalena may be able to go from plant extract to POC human studies within 12-24 months, and the expectation that human studies of Magdalena botanical drug candidates may have a higher probability of success based on the history of human medicinal use of the Magdalena botanical drug candidates. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

1 JAMA Psychiatry. 2013;70(10):1107-1112. doi:10.1001/jamapsychiatry.2013.155

2https://finance.yahoo.com/news/attention-deficit-hyperactivity-disorder-adhd-220000543.html

3 Bromet EJ, Dew MA, Eaton W. Epidemiology of psychosis with special reference to schizophrenia. In: Tsuang MT, Tohen M, Zahner GEP, eds. Textbook in psychiatric epidemiology. New York: John Wiley, 1996:283-300

4https://www.marketresearchfuture.com/reports/schizophrenia-market-1625

Contact Info:

[email protected]

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.



View the original press release on ACCESS Newswire

A.Maldonado--TFWP